Press releases

Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

Key highlights

Explore more press releases

Filter

Topics

Period

Filter by

recent search

Showing: 105 of 210 Press Releases

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – November 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital


Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

PARIS, FRANCE; 03 December 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated…


Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label…


Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association for…


Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital


Your dedicated contacts



How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.